SEC Filing Summary: Organovo Holdings, Inc. (ONVO)
Business Context and Reporting Period
This Form 8-K was filed on August 9, 2024, reporting events occurring on August 5, 2024. The registrant is Organovo Holdings, Inc., a biotechnology company headquartered in San Diego, California. The filing primarily addresses executive compensation arrangements under Item 5.02.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the terms of a new equity grant:
- Option Exercise Price: $0.5368 per share.
- Time-Based Option Shares: 574,923 shares (4.0% of outstanding shares on grant date).
- Performance-Based Option Shares: 431,193 shares (7.0% of outstanding shares on grant date).
Material Changes
On August 5, 2024, the Compensation Committee approved and granted significant stock options to Keith Murphy, Executive Chairman. This represents a material change in the company's equity compensation structure for its leadership. The grant includes a "True-Up" provision: if the company completes an equity financing by March 31, 2025, and the initial options represent less than 4.0% (time-based) or 7.0% (performance-based) of the post-financing share count, additional options will be granted to restore those percentages.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or general business outlook. However, the vesting of the Performance-Based Option is contingent upon achieving specific revenue, market capitalization, stock price, and strategic goals. The "True-Up" provision indicates management's expectation or contingency planning for potential equity financing within the next eight months. No specific risks or contingencies beyond the standard vesting conditions were detailed in this report.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding as of August 5, 2024, to confirm the 4.0% and 7.0% dilution impact.
- Review the specific revenue and market capitalization targets required to vest the performance-based options, as these are not detailed in this filing.
- Monitor for any equity financing announcements prior to March 31, 2025, which would trigger the "True-Up" option grants.
- Confirm the total dilution impact on existing shareholders if both the initial options and potential True-Up options are exercised.